Moderna's stock falls 4% as CEO says enrollment in vaccine trial has been slowed to ensure diversity - MarketWatch

1. Moderna's stock falls 4% as CEO says enrollment in vaccine trial has been slowed to ensure diversity  MarketWatch
2. Vaccine developer Moderna may slow COVID trials to add at-risk minorities  The Jerusalem Post
3. Coronavirus vaccine: The first one may not be the best one  Yahoo Finance
4. Pfizer expects coronavirus vaccine trial results by end of October  CBS Evening News
5. View Full Coverage on Google News

from Top stories - Google News https://ift.tt/32Uk8tW
via